These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 18690502)
21. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs. Tsareva E; Kulakova O; Boyko A; Favorova O Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572 [TBL] [Abstract][Full Text] [Related]
22. Interferon beta-1a treatment and African Americans. Cantor FK Arch Neurol; 2006 Apr; 63(4):627-8; author reply 628. PubMed ID: 16606785 [No Abstract] [Full Text] [Related]
23. Interferon-beta responders and non-responders. A biological approach. Bertolotto A; Gilli F Neurol Sci; 2008 Sep; 29 Suppl 2():S216-7. PubMed ID: 18690496 [TBL] [Abstract][Full Text] [Related]
24. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Weiner HL; Cohen JA Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872 [TBL] [Abstract][Full Text] [Related]
25. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. Smith D J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565 [TBL] [Abstract][Full Text] [Related]
26. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Hadjimichael O; Vollmer T; Oleen-Burkey M; Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588 [TBL] [Abstract][Full Text] [Related]
28. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832 [TBL] [Abstract][Full Text] [Related]
29. Editorial: the pitfalls of combination therapy. Vermersch P Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074 [No Abstract] [Full Text] [Related]
30. Monoclonal antibodies: a target therapy for multiple sclerosis. Lorefice L; Fenu G; Frau J; Coghe G; Marrosu MG Inflamm Allergy Drug Targets; 2014; 13(2):134-43. PubMed ID: 24479836 [TBL] [Abstract][Full Text] [Related]
31. Current approved options for treating patients with multiple sclerosis. Rizvi SA; Agius MA Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672 [TBL] [Abstract][Full Text] [Related]
32. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Rudick RA Neurology; 2003 Nov; 61(9 Suppl 5):S31-4. PubMed ID: 14610110 [TBL] [Abstract][Full Text] [Related]
33. Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies. Rossman IT; Cohen JA Nat Rev Neurol; 2015 Jun; 11(6):316-7. PubMed ID: 25896088 [No Abstract] [Full Text] [Related]
34. Investigational drug therapies of treatment of multiple sclerosis. Panitch HS Mult Scler; 1996 Sep; 2(2):66-77. PubMed ID: 9345383 [TBL] [Abstract][Full Text] [Related]
35. Effects of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis. Totaro R; Passacantando A; Russo T; Parzanese I; Rascente M; Marini C; Tonietti G; Carolei A Int J Immunopathol Pharmacol; 2005; 18(2):377-83. PubMed ID: 15888259 [TBL] [Abstract][Full Text] [Related]
36. Development of resistance to biologic therapies with reference to IFN-β. Farrell RA; Marta M; Gaeguta AJ; Souslova V; Giovannoni G; Creeke PI Rheumatology (Oxford); 2012 Apr; 51(4):590-9. PubMed ID: 22258390 [TBL] [Abstract][Full Text] [Related]
38. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Mendes A; Sá MJ Arq Neuropsiquiatr; 2011 Jun; 69(3):536-43. PubMed ID: 21755136 [TBL] [Abstract][Full Text] [Related]
39. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Stuart WH Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719 [TBL] [Abstract][Full Text] [Related]